Answers are grounded in this paper and cite their sources.
Biannual mass azithromycin distributions reduce childhood mortality in Sub-Saharan Africa. However, stakeholders have struggled to balance this short-term benefit against the potential long-term risk of antibiotic resistance. Here, we monitor resistance in 286 community surveys in Niger over 8 years of biannual azithromycin distributions to pre-school children. Communities were randomized to either azithromycin or placebo at 3 timepoints, allowing assessment of the effects of recent treatment, cumulative treatment, and secular trend. Macrolide resistance genes found in the stool of pre-school children increased during the first 3 years of intervention (the first 6 biannual distributions). Assessment at 4½, 6, and 8 years (after 9, 11, and 15 biannual distributions, respectively) failed to detect any further incremental increase. When distributions were discontinued, macrolide resistance decreased to pre-treatment levels. Beta-lactam resistance increased significantly over the 8 years. This increase was not associated with the mass azithromycin distributions and may represent a secular trend in the region. Mass azithromycin distribution for childhood mortality clearly selects for macrolide-resistant bacteria. This resistance apparently plateaus after 3 years of intervention, remains limited to macrolide antibiotics, and returns to baseline after distributions are discontinued. Monitoring can inform whether the benefit of improved childhood survival with azithromycin distributions continues to outweigh any long-term harm from antibiotic resistance.
No takes yet. Share an insight, caveat, or question.
Lietman et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: